Review Article

Biological Aging and Immune Senescence in Children with Perinatally Acquired HIV

Annalisa Dalzini,1 Maria Raffaella Petrara,1 Giovanni Ballin,1 Marisa Zanchetta,2 Carlo Giaquinto3 and Anita De Rossi1,2

1Section of Oncology and Immunology, Department of Surgery, Oncology and Gastroenterology, Unit of Viral Oncology and AIDS Reference Center, University of Padova, Padova, Italy
2Veneto Institute of Oncology IOV – IRCCS, Padua, Italy
3Department of Mother and Child Health, University of Padova, Padova, Italy

Correspondence should be addressed to Anita De Rossi; anita.derossi@unipd.it

Received 31 January 2020; Accepted 22 April 2020; Published 16 May 2020

Guest Editor: Lesley De Armas

Copyright © 2020 Annalisa Dalzini et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Chronic HIV-infected children suffer from premature aging and aging-related diseases. Viral replication induces an ongoing inflammation process, with the release of pathogen-associated molecular patterns (PAMPs) and damage-associated molecular patterns (DAMPs), the activation of the immune system, and the production of proinflammatory cytokines. Although combined highly active antiretroviral therapy (ART) has significantly modified the natural course of HIV infection, normalization of T and B cell phenotype is not completely achievable; thus, many HIV-infected children display several phenotypical alterations, including higher percentages of activated cells, that favor an accelerated telomere attrition, and higher percentages of exhausted and senescent cells. All these features ultimately lead to the clinical manifestations related to premature aging and comorbidities typically observed in older general population, including non-AIDS-related malignancies. Therefore, even under effective treatment, the premature aging process of HIV-infected children negatively impacts their quality and length of life. This review examines the available data on the impact of HIV and ART on immune and biological senescence of HIV-infected children.

1. Introduction

The natural history of HIV infection has greatly changed over the course of the last 20 years due the great improvement of the combined highly active antiretroviral therapy (ART). Compared to the past, life expectancy of HIV-infected individuals on ART has drastically increased; however, ART does not eradicate the infection; therefore, HIV will persist in infected individuals, becoming a chronic disease [1]. Although some studies suggested that, under optimal treatment, life expectancy could be similar to that of the uninfected population [2–4], other studies evidenced that this goal has not been achieved yet, and life expectancy in Western countries can be shortened of up to 10 years [5–8]. AIDS-related complications, among which opportunistic infections and AIDS-defining malignancies, are reduced compared to the past; however, HIV-infected individuals on ART still have a higher risk of non-AIDS-related morbidity and mortality, due to an increased incidence of a wide range of illnesses associated with aging [9, 10].

Aging is a natural process that involves the loss of physiological integrity with a generalized organ decline that ultimately leads to death [11]; an aging system faces a decreasing ability to deal with stress and increasing frailty [12–15], inflammation [12], and age-related comorbidities, including cardiovascular disease, neuropathy, anemia, osteoporosis, and liver and kidney disease [11, 16]. The persistence of HIV, causing chronic immune activation, is likely a key determinant of the premature senescent pathway. Indeed, viral persistence induces activation of immune system cells,
which undergo continuous expansion as a response to the antigen, eventually reaching the senescent stage, when they lose their functions [17]. A direct consequence of cellular replication is the shortening of their telomeres, until they reach a critical length under which the replicative capacity of the cell is lost [18–20], fueling the cells’ premature senescence and the development of those age-related diseases that are involved the loss of the regenerative capacity of different tissues [21]. It is nowadays well established that there is a link between telomere shortening, cellular senescence, and aging [22]. In addition, HIV itself can impair the activity of telomerase (a ribonucleoprotein enzyme complex that synthesizes the telomeric repeats TTAGGG [23, 24]) specifically in CD4 cells [25]. The importance of this adverse effect resides on the fact that although telomerase is usually not expressed in somatic cells, it can be transiently upregulated in lymphocytes upon cell activation [26, 27]; the impairment of this upregulation can therefore increase the apoptotic propensity of hematologic cells and lead to immune system dysfunction.

Currently about 38 million people are living with HIV; 2 million of them are children under 15 years of age. Although new HIV infections among children are steadily decreasing, still, 16,000 new infections occurred in 2018, the vast majority of them being mother-to-child transmission (MTCT) in African countries [28]. The clinical complications of HIV infection in children are more serious than those in adults [29–32]. Indeed, they experience a poorer control of the disease, which progresses to AIDS faster [29, 33], and the acute stage of the infection is characterized by higher levels of viremia, which is controlled slower and less effectively than in adults [33–35]. Several studies conducted in children [36–39] suggest that possible causes of the differences mentioned above include the very early exposure to HIV and pathogens when the infants’ immune system is still under development, an interaction that could also influence the evolution of their incomplete immune system.

Thanks to the continuously increasing coverage of ART-based prophylaxis and treatment, in 2018, MTCT incidence was under 2%, and about 50% of HIV-infected children were receiving ART [28]. Therefore, an increasing number of children start ART at a very young age and will be receiving antiretroviral drugs for all their lifetime. ART greatly improved their survival and the quality of life [40, 41], but on the other hand, they now face the consequences of a lifelong chronic condition, suffering from pathogenic mechanisms typical of premature aging [42–46]; i.e., they show an increased risk of age-associated comorbidities, identified as non-AIDS-related diseases [47–49], compared to healthy individuals [50–52]. It has been suggested that antiretroviral drugs themselves can impact on accelerated aging, mainly due to the inhibitory effect of nucleoside reverse transcriptase inhibitors (NRTIs) on telomerase [53, 54]; however, more recent studies argued that the effect of prophylaxis and therapy is negligible compared to that of the HIV infection itself [55, 56].

In this review, we examine the available data on how HIV and/or ART impact on immune and biological senescence of HIV-infected children. The impact of HIV with and without ART is schematized in Figure 1.

2. Clinical Conditions Related to Premature Aging of HIV-Infected Children

Despite the significant improvements due to ART introduction, the life span of HIV-infected children is not yet comparable to that of uninfected ones: their premature aging exposes them to a higher risk of acquiring and developing age-related chronic diseases. The continued release of virions by residual replicating virus (that persists at low levels even in the presence of effective ART) promotes a chronic inflammatory status, in which the release of proinflammatory cytokines favors premature cellular aging and the pathophysiological scenario typically observed in elderly persons. This includes renal and cardiovascular diseases, metabolic and endocrine alterations, cerebrovascular diseases, and malignancies [42–46, 57–59]. Here, we focus on malignancies diagnosed in HIV-infected children.

As happens for HIV-infected adults [60], HIV-infected children show a higher frequency of malignancies compared to the general population [45, 61–65]. In the pre-ART era, the risk of malignancy occurrence was mainly linked to the immunological dysfunction per se and lack of adaptive immune response against oncogenic viruses. Kaposi sarcoma (KS) and non-Hodgkin lymphoma (NHL), the two AIDS-defining malignancies (ADM) most frequent in children [61], are indeed associated with Human gammaherpesvirus 8 (HHV8) and Epstein-Barr Virus (EBV), respectively [45, 66–68]. ART introduction led to a change in the nature of HIV-related malignancies, with a reduced incidence of ADM (e.g., KS -87% and NHL -60% [69]) and increased incidence of non-ADM (including Hodgkin’s disease, anal cancer, oral squamous carcinoma, hepatocarcinoma, leiomyosarcoma, and Merkel cell carcinoma [45]), especially among immunocompromised HIV-infected children who have received ART for a reduced period of time [61, 70]. The decrease in the incidence of ADM may be attributable to recovery of CD4 cells, partial restoration of immune functions, and lower immune activation, induced by effective ART. As an example, Petrina et al. [71] suggested that limiting HIV replication and related microbial translocation and immune activation may prevent superinfection with EBV or lower EBV viremia, thus reducing the risk of EBV-associated NHL. ART, however, can only partially revert the increased expression of all factors leading to chronic immune activation [72], due to the persistence of residual viremia. Chronic immune activation, with increased cell turnover and premature immune senescence, is indeed associated with the increased risk of non-ADM malignancies in HIV-infected children [17, 67, 73]. The genetic instability conferred by accelerated telomere erosion and the hampered immune surveillance may promote cancer development [74]. Moreover, senescent cells furtherly fuel tumor growth by secretion of inflammatory cytokines, growth factors, and proteases [75, 76], establishing a tumorigenic microenvironment.

3. Premature Immune Senescence

The main target of HIV virus is immune cells, in particular CD4 lymphocytes, monocytes, and macrophages [77]. HIV infection leads indeed to a severe depletion of CD4 cells
and a progressive loss of function of the innate and adaptive immune system [78]. Despite ART effectiveness, residual HIV infection still has consequences on the immune phenotype of the host: HIV-driven immune senescence is indeed one of the leading contributors to the premature aging displayed by HIV patients [79, 80]. A senescent immune system, characterized by the accumulation of functionally impaired differentiated immune cells, compromises the immune response [81], hampering the ability to react to novel antigen challenges and contributing to frailty [82].

One of the main peculiar features of the children immune system, compared to that of the adults, is their much higher thymic output [23] that constitutes an advantage over adults in the context of HIV infection. On the other hand, the immune system of children exposed to HIV has not yet fully developed when they meet the virus, therefore, leaving them unable to mount an efficient immune response; therefore, the consequences of HIV in this case are more complex and the disease has a faster progression [29]. Moreover, children are exposed to the virus from an early age, in most cases from birth: despite the benefits of an effective therapy, the lifelong exposure to the virus and to the drugs promotes a chronic activation of the immune system, contributing to its premature aging. The main alterations on the immune phenotype of HIV-infected children are described in detail below.

3.1. T Cell Compartment. Many alterations in the CD4 and CD8 cell subsets have been reported for all HIV-infected
individuals and in particular for children and infants [83–86]. The main alteration in the immune phenotype is the inversion of the CD4/CD8 ratio, which is considered a hallmark of disease progression: whereas a normal CD4/CD8 ratio is above 1, untreated individuals with HIV undergo CD4 depletion, which results in a CD4/CD8 ratio below 1. Several children and adults on ART, despite reaching virological suppression, may not recover to a normal CD4/CD8 ratio, an effect attributable both to incomplete recovery of CD4 and to the increase of CD8 cells due to persistent immune activation. About 66% of HIV-infected children, however, succeed to recover to a normal CD4/CD8 ratio [87], a percentage higher than the one observed in adults [88]; the 33% of children who do not recover are usually older and/or have started ART later. This difference in the ability to restore a normal CD4/CD8 ratio has been partially explained with the increased expansion of T regulatory (Treg) cells of children compared to adults and by the better proliferative capacity of their HIV-specific T cells [89]. Conversely, a study [90] showed that defective recovery of the CD4/CD8 ratio is instead associated to increased levels of activated, senescent and effector memory T cells, with decreased naive T cells. Overall, the whole CD4 and CD8 T cell populations are affected by HIV, even in individuals on effective ART [59].

Naïve T cells undergo a drastic reduction due to thymus involution [91] and to frequent stimulation and expansion of preexisting populations of antigen-specific T cells in the struggle to regenerate the T cell pool [81]. Several studies [84, 92–94] pointed out, indeed, a loss of naïve CD4 and CD8 (CD45RA+CCR7+) cells both in adults and in children; at the same time, a decrease of central memory in favor to the effector memory (CD45RA-CCR7-), with the expansion of CD27-, marker of effector type T cells [95], was detected. Another study [36] compared HIV-infected, HIV-exposed uninfected (HEU), and HIV-unexposed uninfected (HUU) infants, showing that, over the first year of life, CD8 naïve, memory, effector, terminally differentiated, and senescent T cells were significantly altered in HIV-infected infants compared to the other two groups; in particular, CD8 naïve cells were significantly lower, while CD8 effector memory, terminally differentiated (CD45RA+CCR7-), and senescent (CD28-CD57+) cells were significantly higher. A study on 57 perinatally HIV-infected adolescents [39] showed increased levels of senescence and proliferation (Ki67+) markers in the memory CD4 cell subset, compared to healthy subjects; their effector memory cells were also positive for activation marker HLA-DR. A recent study [56] compared 71 HIV-infected children below 5 years of age to HEU and HUU cohorts, observing an accelerated senescence of both their CD4 and CD8 cell compartments, with significantly higher percentages of activated (CD38+HLA-DR+) and exhausted (programmed cell death, PD-1+) CD4 cells and of activated, senescent, and exhausted CD8 cells; interestingly, the exposure to ART prophylaxis of HEU children did not negatively affect their immune phenotype.

Other studies confirmed that HIV-infected children display higher percentages of exhausted T cells, which often fail to recover despite treatment [96, 97]; PD-1 expression, the principal marker of HIV-related cell exhaustion, has indeed been proposed as a disease progression marker [97]. Recently, additional immune checkpoint inhibitors (ICIs), including CTLA-4, TIM3, LAG3, TIGIT, 2B4, and CD160, were identified; they were found to coexpress especially in viremic progressors, furtherly inhibiting T cell function [98]. In spite of the promising potential of ICIs as progression markers, exploring their expression in HIV-infected children is still an open field of research.

T follicular helper (Tfh) cells are specialized CD4 cell subset whose signaling function allows the generation of long-lived B cells during the immune response. Indeed, they are considered a biomarker of vaccine response. The equilibrium between their different subsets (i.e., Th1, Th2, and Th17) and their function is perturbed during HIV infection, even under virological control, resulting in an impaired response to vaccination. In particular, in HIV-infected children, a negative response to vaccination has been associated with Tfh cells coexpressing multiple activation markers [110, 111].

Increased immune senescent phenotype in HIV-infected children has been pointed out by many studies [38, 112, 113]. Moreover, the persistent immune activation and exhaustion, together with alterations of memory T cells, may also have an impact on the efficacy of childhood vaccination and have been linked to poor response to vaccines and higher risk to acquire vaccine-preventable diseases [36, 111–117].

3.2. B Cell Compartment. The B cell compartment is impacted by similar alterations as those affecting T cells: indeed, several studies [114, 118, 119] demonstrated that HIV-infected children, even with undetectable viral load, show B cell alterations typical of older healthy controls, such as an increased number of mature-activated (CD10-CD21+) and senescent double-negative (IgD-CD27-) B cells. Other B cell alterations linked with chronic HIV persistence include increased percentages of immature transitional (CD10+CD21low/high CD27-), activated memory (CD10-CD21low CD27+), and exhausted memory (CD10-CD21low CD27-) B cells and decreased percentages of resting memory (CD10-CD21high CD27+) B cell subset [120, 121]. A study [122] on ART-naïve children below 2 years of age revealed many alterations of their B cell phenotype compared to the uninfected control group; they had significant depletion of naïve (IgD+CD27-), nonswitched memory (NSM, IgD+
have higher levels of viral suppression, children with perinatally acquired HIV immunological and structural abnormalities persist in the gastrointestinal tract occurs at a much slower pace, and both reconstitution in peripheral blood, reconstitution of the gas-

ART in HIV-infected subjects generally allows for immune reconstitution in peripheral blood, reconstitution of the gastrointestinal tract occurs at a much slower pace, and both reconstitution in peripheral blood, reconstitution of the gas-

1-year follow-up, with further depletion of naive and NSM cells and expansion of double-negative B cell subset. On the other hand, one year of ART could only partially restore these alterations: there was an increase in the naive, NSM, and naive mature cell subsets and a decrease in the double-negative, activated memory, and TLM subsets; however, no improvement was found in the resting memory, activated, and apoptosis-prone B cell subsets that remained significantly altered. Thus, as for T cell compartment, ART does not fully restore B cell functionality. Notably, despite ART, homing of B cells to germinal center is affected with the consequent impaired vaccine responses in HIV-infected children [114, 123, 124]. In addition, the expression of B cell genes, including those involved in the inflammation and aging, that could predict the response to vaccination [125, 126], remains perturbed even after a stable and long virological control.

4. Chronic Immune Activation and Persistent Inflammation

Persistent inflammation and chronic immune activation are leading causes of the senescent pathway that favors the risk of non-AIDS morbidity and mortality in HIV-infected chil-

1-year follow-up, with further depletion of naive and NSM cells and expansion of double-negative B cell subset. On the other hand, one year of ART could only partially restore these alterations: there was an increase in the naive, NSM, and naive mature cell subsets and a decrease in the double-negative, activated memory, and TLM subsets; however, no improvement was found in the resting memory, activated, and apoptosis-prone B cell subsets that remained significantly altered. Thus, as for T cell compartment, ART does not fully restore B cell functionality. Notably, despite ART, homing of B cells to germinal center is affected with the consequent impaired vaccine responses in HIV-infected children [114, 123, 124]. In addition, the expression of B cell genes, including those involved in the inflammation and aging, that could predict the response to vaccination [125, 126], remains perturbed even after a stable and long virological control.

4. Chronic Immune Activation and Persistent Inflammation

Persistent inflammation and chronic immune activation are leading causes of the senescent pathway that favors the risk of non-AIDS morbidity and mortality in HIV-infected children. T cell activation, marked by CD38 and HLA-DR coexpression on CD8 T cells, is a prognostic indicator for disease progression at different stages of HIV infection [127]. Moreover, HIV infection drives the microbial translocation [128]: the massive depletion of CD4 cells associated with HIV infection induces an impairment of mucosal surface integrity in the gut and leads to the release of pathogen-associated molecular patterns (PAMPs, such as bacterial lipopolysaccharide, 16S ribosomal DNA, and CpG DNA [55]) and damage-associated molecular patterns (DAMPs, such as mitochondrial DNA, high-mobility group box 1 protein, and defensins [129, 130]) into the circulation. PAMPs and DAMPs activate the immune system by binding to the extra- or intracellular domain of Toll-like receptors (TLRs), which are involved in the host inflammatory response, initiating a complex-signal transduction cascade which, via the NF-kB pathway [131], ultimately leads to increased transcription of proinflammatory cytokines (such as IL-6, IL-10, and interferon-α) that may play a role in establishing a protumorigenic inflammatory environment [66].

Several studies [132–134] have suggested that, despite viral suppression, children with perinatally acquired HIV have higher levels of inflammation, immune activation, and alterations in intestinal permeability, compared to HEU and HUU children. Notably, immune activation is higher in viremic than aviremic children, but microbial translocation may occur regardless of viremia and T cell activation. While ART in HIV-infected subjects generally allows for immune reconstitution in peripheral blood, reconstitution of the gastrointestinal tract occurs at a much slower pace, and both immunological and structural abnormalities persist in the gastrointestinal tract, thus explaining the residual inflammation and heightened morbidities in HIV-infected ART recipients [135]. In a cohort of HIV-infected children [136], ART initiation rapidly and persistently reversed T cell activation but failed to normalize CD4/CD8 ratios and plasma sCD14 levels. However, another study on a cohort of perinatally HIV-infected children [137] showed that ART initiation normalized sCD163 (marker of monocyte activation) levels and improved long-term pediatric outcomes. A recent study [138] agreed that immune activation decreases over time in children after starting ART, which does not have adverse effects itself on microbial translocation.

To support the concept that persistent immune activation and cellular exhaustion are closely linked to accelerated biological aging and immune senescence, Gianesin et al. [56] found that HIV-infected children accumulate activated and exhausted CD8 T cells together with a higher percentage of senescent CD8 T cells, which are all inversely correlated with telomere length. The immune exhaustion is also increased in HIV-infected individuals despite viral suppression [139]. Indeed, PD-1 is the eligible marker of immune exhaustion of T cells, and its increased expression levels predict the rate of HIV disease progression in adults [140, 141]. HIV-infected children have increased PD-1 expression on CD8 T cells that correlates with immune activation [142, 143]. It was recently demonstrated that CD4 cells expressing PD-1 constitute an important source of persistent viral replication in ART-treated individuals, and the contribution of PD-1+ CD4 cells to the persistent reservoir progressively decreased with increased length of ART [144].

Immune activation also results in chronic stimulation and expansion of B cells. ART allows, at least partially, the normalization of activated B cell subsets and age-dependent accumulation of resting memory B cells [145]. However, as for T cell, ART does not eliminate B cell activation. In HIV-infected adults, immune activation persists over time and is susceptible to therapy; indeed, compared to classical combined ART, a monotherapy with protease inhibitors has a lower control on DAMP levels and B cell hyperactivation, so it may have lower control on EBV reactivation and/or polyclonal expansion of EBV-infected B cells and, thus, on the onset of EBV-related malignancies [146]. Few data are available about B cell activation in HIV-infected children. A study [71] demonstrated that children on ART have significant lower levels of microbial translocation and EBV levels than ART-naïve children. Recently, a study [147] showed that pre-ART progressors had higher percentages of mature activated and TLM cells and higher plasma levels of IL-4, IL-6, IL-10, and IgA compared to seronegative controls. After ART initiation, levels of proinflammatory cytokines IL-4, IL10, and IgG significantly lowered.

Overall, all these reports agree that, despite ART, micro-

bial translocation persists and leads to a chronic low-grade inflammation. In HIV-infected children, the monitoring of persistent inflammation/immune activation and immune exhaustion will be of clinical importance to estimate the rate of premature aging and its associated production of inflam-

matory cytokines, as pivotal factors acting in the pathogene-

sis of premature aging and malignancies.
5. Premature Biological Aging

Telomeres are involved in cellular aging and immune senescence mechanisms. Telomeres are long tandem repeated DNA sequences (TTAGGG) at the end of chromosomes that are essential for protection of chromosome integrity, preventing end-to-end fusion and DNA degradation [148]. The ribonucleoprotein complex telomerase has the function of maintaining telomeres by synthesizing new telomeric repeats; its activity is usually not detected in somatic cells due to the downregulation of its catalytic protein TERT, which is instead expressed during embryogenesis, in rapidly dividing tissues and in the vast majority of tumors [148]. During each cell division, DNA polymerase is unable to copy the end of chromosomes (the end-replication problem); thus, some of the telomere repeats are lost. After several cell divisions, telomere length reaches a critical threshold, below which cells stop dividing and physiologically undergo senescence or trigger genomic instability, that may promote age-associated diseases and tumor development [149].

Telomeres get naturally shorter with age [150]; telomere length is therefore a valid biomarker of aging in the general population, and accelerated telomere shortening leads to premature aging, which is correlated with several pathologies [151, 152]. The causes leading to accelerated telomere shortening can be, however, diverse. Indeed, telomere length and their shortening rate are not only associated with genetic factors, gender, and ethnicity, but they are also influenced by different behavioral and environmental factors, such as stress, physical activity, dietary habits, smoke, and alcohol consumption.

5.1. Telomere Implications in Diseases. Telomere length is associated with age-related diseases and decreased life span. Several studies linked shorter telomeres and telomere attrition with increased risk and increased severity of cardiovascular diseases, stroke, heart attack, and mortality [153–159]. As an example, a study on elderly patients [153] showed that, among the 143 studied patients, the 71 with shortest telomeres had a 3- and 8-fold higher mortality rate due to heart and infectious diseases, respectively. Premature aging disorders, among which progeria, Nijmegen breakage, Cockayne and Down syndromes, and dyskeratosis congenita are associated with shorter telomeres; instead, others like Werner and Bloom syndromes and Ataxia telangiecisia are associated with an accelerated telomere shortening [160]. In contrast to the clear association of the aforementioned aging conditions with telomere length or erosion, similar studies on other conditions raised conflicting results: it is not yet fully cleared whether type II diabetes [161, 162] and Alzheimer’s [163–167] and Parkinson’s [168, 169] diseases are associated with telomere shortening or if having shorter telomeres is a risk factor for such conditions. Moreover, telomere dynamics is intrinsically related with the tumorigenesis mechanism. Indeed, shortening of telomeres below a critical level triggers the pathways that lead to cell senescence, when genomic instability is increased [170]. Should the apoptotic mechanism fail, cells may acquire immortality (mainly through the upregulation of telomerase) and, thus, tumorigenesis mechanisms may begin. Telomeres have therefore the potential to be both beneficial and detrimental factors, whether they are recognized in the signaling pathway resulting in cell apoptosis or not. In agreement with this dual role, some types of cancers have been associated with shortened telomeres while others with elongated telomeres [171].

Telomeres are not only involved in diseases affecting the elderly population, but they also have a role in conditions affecting children and adolescents. A recent study [172] on 62 children and adolescents diagnosed with AATD (α1-antitrypsin deficiency) and with intermediate to high risk for developing lung or liver damage showed that they had significantly shorter telomeres and increased oxidative stress than controls; high-risk patients showed not only shorter telomeres but also lower TERT expression and decreased telomerase activity than the other groups. Another study [173] on 44 patients, among which 26 children, with inherited telomere biology disorders (such as dyskeratosis congenita, Hoyeraal-Hreidarsson, and Revesz syndrome) showed that 57% of them had at least one structural brain abnormality or variant; they also had psychiatric diagnoses and other diseases more frequently than the general population. Another confirmation comes from a study [174] conducted on 47 young adults (17-24 years old) diagnosed with the premature aging syndrome of Prader-Willi (PWS). They displayed significantly shorter telomere length compared to age-matched healthy controls; they also showed a mild association with lower IQ. Childhood cancers sometimes need to be addressed differently from adult ones; one of the reasons resides in the differences in the mutational landscapes and the prevalence of telomere maintenance mechanisms [175]. Environmental and behavioral factors might also impact on telomere length and erosion in newborns, children, and adolescents. For example, a study on 762 mother-newborn pairs in China [176] demonstrated that prenatal exposure to some phthalate metabolites was associated with shorter cord blood telomere length; this study was also an evidence that intrauterine environment has the potential to impact newborns’ telomere length. Different studies on European cohorts [177, 178] showed that higher child adiposity indicators are associated with short telomeres in children; overweight and obesity in childhood and adolescence are associated with shorter telomeres; therefore, an increased BMI early in life may be associated with accelerated biological aging and may have an adverse impact on future health during adulthood.

To summarize, telomere length has the potential to have a valid diagnostic significance in specific settings. A recent work by Alder et al. [179] measured telomeres of 100 individuals with known pathogenic mutations in telomerase and other telomere maintenance genes, compared with those of 636 healthy individuals of all ages. All of the 100 patients had age-adjusted telomere length below the 50th percentile: this indicated a 100% negative predictive value for identifying a clinically relevant mutation in telomerase/telomere maintenance genes. Moreover, a significant correlation was found between faster telomere attrition and earlier onset of idiopathic bone marrow failure; 25% of the idiopathic bone marrow failure patients had their treatment regimen choice modified based on their telomere length measurement, resulting in an improvement of their clinical outcomes.
Table 1: Summary of recent findings on telomeres on HIV-infected children, adolescents, and young adults.

| Patients          | Median age [IQR] (y.o.) | Telomere length median [IQR] | Method of telomere measure | Main findings                                                                 | Authors and reference |
|-------------------|-------------------------|------------------------------|-----------------------------|-------------------------------------------------------------------------------|-----------------------|
| 94 pHIV           | 13.3 [9.9-15.8]         | n.d.                         | Relative TL by rtPCR        | Telomere attrition is similar for pHIV, HEU, and HUU. Older age and male gender are correlated with shorter TL. Detectable viremia and absence of ART are correlated with shorter TL. | Cote et al. [37]     |
| 177 HEU           | 1.7 [0.6-4.0]           | n.d.                         |                            | pHIV have significantly shorter TL than HEU and HUU. ART-naive pHIV have shorter TL than pHIV on ART. Percentages of senescent, activated, and exhausted CD8 cells are higher in pHIV than in HEU and HUU. | Gianesin et al. [56]  |
| 104 HUU           | 10.6 [5.3-14.2]         | n.d.                         | Relative TL by rtPCR        | Absolute telomere length was shorter in pHIV and HEU compared to HUU but did not differ between pHIV and HEU. | Ajaykumar et al. [191]|
| 71 pHIV           | 3.11 [1.40-4.48]        | 2.21 [1.94-2.58]             | Absolute TL by rtPCR        | There was no evidence of accelerated biological aging by mDNA levels.         | Shiau et al. [193]   |
| 65 HEU            | 1.74 [0.99-3.31]        | 2.63 [2.25-3.21]             |                            | Absolute telomere length was shorter in pHIV and HEU compared to HUU but did not differ between pHIV and HEU. |                      |
| 56 HUU            | 1.85 [0.84-3.46]        | 2.88 [2.49-3.10]             | Relative TL by rtPCR        | TL is similar between HEU and HUU. HIV and cART exposure in utero does not appear to alter telomere dynamics during early life. |                      |
| 324 HEU           | ≥1 samples 0-3 y.o.     | n.d.                         | Relative TL by rtPCR        | TL is similar between HEU and HUU. HIV and cART exposure in utero does not appear to alter telomere dynamics during early life. |                      |
| 306 HUU           | 1 sample 0-3 y.o.       | n.d.                         | Relative TL by rtPCR        | TL is similar between HEU and HUU. HIV and cART exposure in utero does not appear to alter telomere dynamics during early life. |                      |
| 120 pHIV          | 6.4 ± 1.4               | 4.14 ± 0.85                  | Absolute TL by rtPCR        | Absolute telomere length was shorter in pHIV and HEU compared to HUU but did not differ between pHIV and HEU. |                      |
| 33 HEU            | 6.1 ± 1.5               | 4.05 ± 0.74                  | Absolute TL by rtPCR        | Absolute telomere length was shorter in pHIV and HEU compared to HUU but did not differ between pHIV and HEU. |                      |
| 25 HUU            | 6.9 ± 1.1               | 4.53 ± 0.79                  | Absolute TL by rtPCR        | Absolute telomere length was shorter in pHIV and HEU compared to HUU but did not differ between pHIV and HEU. |                      |
| 94 HEU ZDV+       | 1.0 [0.0-7.0] days      | 0.85 ± 0.23                  | Relative TL by rtPCR        | TL of ZDV+HEU infants is longer compared to that of ZDV-HEU.                   | Wang et al. [192]    |
| 85 HEU ZDV-       | 1.0 [0.0-6.9] days      | 0.65 ± 0.19                  | Relative TL by rtPCR        | TL and telomere shortening rate of pHIV and npHIV is significantly lower than that of HUU. pHIV and npHIV maintain a normal thymic output, with a continuous shift of the naïve pool into memory subsets. This phenomenon may allow to control viral infection and maintain peripheral homeostasis. | Paghera et al. [194]|
| 21 pHIV           | 27 [24-29]              | 1.0 [0.8-1.2]*               | Relative TL by rtPCR        | TL and telomere shortening rate of pHIV and npHIV is significantly lower than that of HUU. pHIV and npHIV maintain a normal thymic output, with a continuous shift of the naïve pool into memory subsets. This phenomenon may allow to control viral infection and maintain peripheral homeostasis. | Paghera et al. [194]|
| 19 npHIV          | 27 [24-29]              | 0.9 [0.7-1.2]*               | Relative TL by rtPCR        | TL and telomere shortening rate of pHIV and npHIV is significantly lower than that of HUU. pHIV and npHIV maintain a normal thymic output, with a continuous shift of the naïve pool into memory subsets. This phenomenon may allow to control viral infection and maintain peripheral homeostasis. | Paghera et al. [194]|
| 40 HUU            | 28 [24-31]              | 1.5 [1.3-1.9]*               | Relative TL by rtPCR        | TL and telomere shortening rate of pHIV and npHIV is significantly lower than that of HUU. pHIV and npHIV maintain a normal thymic output, with a continuous shift of the naïve pool into memory subsets. This phenomenon may allow to control viral infection and maintain peripheral homeostasis. | Paghera et al. [194]|

pHIV: perinatally HIV-infected children; npHIV: nonperinatally HIV-infected children; HEU: HIV-exposed uninfected children; HUU: HIV-unexposed uninfected children; HUU: HIV unexposed uninfected; ZDV: zidovudine; TL: telomere length; n.d.: values not reported in the original papers; *values estimated from Figure 2A of Paghera et al. [194].
5.2. Telomere Shortening in HIV-Infected Children and Impact of ART. There is nowadays evidence that HIV-infected individuals have overall shorter telomeres than uninfected controls [180–183], implicating that HIV directly influences telomere attrition, which occurs early after infection [184]. It has also been suggested that antiretroviral drugs themselves can impact on accelerated aging. Indeed, HIV reverse transcriptase shares homology with TERT [148, 185, 186]; therefore, nucleoside reverse transcriptase inhibitors (NRTIs), such as zidovudine (ZDV) or abacavir, might also inhibit TERT. In vitro studies showed that NRTIs inhibit telomerase causing an accelerated erosion of telomeres [53, 54, 187, 188]; recent studies argued that the effect of prophylaxis and therapy is negligible compared to that of the infection itself [56]. However, two studies published in 2018 still reported apparently conflicting results on the impact of different NRTI regimens on patients’ telomere length and their change over time [189, 190]. The main findings of the papers presented in this paragraph are also summarized in Table 1.

A study [37] on 94 0–19-year-old HIV-infected children found no significant differences in their relative telomere length compared to that of exposed (HEU) and unexposed (HUU) uninfected controls. However, in the HIV-positive group, higher viral load was associated with shortening of telomeres. To investigate the impact of NRTIs on children’s telomeres, a study was conducted on 114 HEU infants exposed to ZDV prophylaxis [191]; their telomeres at birth were similar to those of HUU controls, and no association was found between telomere length and maternal ART regimen. Among the 114 HEU children, those exposed to maternal ZDV+lamivudine+nelfinavir/nevirapine regimen had longer telomeres at birth. Moreover, telomere attrition in HEU children was more rapid in their longer telomeres at birth. Moreover, telomere attrition in immune senescence profiling (CRP, and sCD14). Only one study [56] analyzed both the relationship between telomere length and markers of inflammation/immune activation (IL-6, TNF-α, high-sensitivity CRP, and sCD14). Only one study [56] analyzed both the immune senescence profile and telomere length in 0–5-year-old HIV-infected, HEU, and HUU children. In this study, telomeres were significantly shorter in HIV-infected children compared to HEU and HUU ones; moreover, among the HIV-infected children, telomeres were shorter in ART-naïve than in ART-treated children. HIV-infected children also displayed significantly higher percentages of senescent (CD28-CD57+), activated (CD38+HLADR+), and exhausted (PD1+) CD8 T cells, while these percentages were comparable between HEU and HUU children. The inverse correlation found between activated, exhausted, and senescent CD8 cells and telomere length corroborated the idea that persistent immune activation is closely linked to accelerated biological aging and immune senescence.

Given the need of maintaining children with HIV on ART for their entire life span, it is of interest to investigate the long-term consequences of perinatally acquired HIV. A 2019 study [194] investigated telomere length and erosion, together with thymic and bone marrow output, of young adults (median age 27 years old) who acquired HIV perinatally compared to age-matched individuals infected later in life. Both groups showed a normal thymic output and normal CD4 count; however, both groups had shorter telomeres and a faster telomere erosion compared to uninfected age-matched controls. This apparent discrepancy has been explained proposing that the attempt to control the infection continuously recruits naïve cells, which shift to the memory phenotype. Moreover, the positive correlation that was found between CD4 count and telomere length in both HIV-infected groups further supports the concept that CD4 cells are newly recruited cells which underwent fewer cell divisions.

The collection of these data supports the idea that HIV infection itself has the major detrimental impact on cellular aging, and ART benefits strongly outweigh the negative effects on telomeres.

6. Conclusions

ART has changed the natural history of HIV, which is now considerably a chronic disease. Despite effectiveness of treatments, HIV-infected children still do not have the same life expectancy and quality of life compared to the general population. Perinatally infected children acquire the virus early, when their immune system has not yet reached full development and they are unable to mount efficient immune response, so the disease has a faster progression. A persistent state of inflammation and activation of the immune system contributes to establishing a premature aging profile. This cannot be fully reverted by ART, representing one of the main causes of comorbidities/malignancies in treated HIV-infected children. Accumulating evidence demonstrated that the beneficial effects of ART greatly outweigh the potential side effects of NRTI use; indeed, it is mainly HIV that induces telomere attrition and premature aging. In this setting, the monitoring of markers of inflammation/immune activation and premature aging is of great clinical relevance. Early-treated children with reduced inflammatory and senescent status could reveal optimal candidates for future treatments and vaccine trials.

Conflicts of Interest

The authors declare that there is no conflict of interest regarding the publication of this paper.

Acknowledgments

This work was supported by Paediatric European Network for treatment of AIDS (PENTA) Foundation. AD was...
supported by PENTA, within the EPICAL project. MRP was supported by University of Padova, BIRD (181981/18), and Associazione Italiana Ricerca sul Cancro (AIRC) (IG-19112).

References

[1] S. G. Deeks, S. R. Levin, and D. V. Havlir, “The end of AIDS: HIV infection as a chronic disease,” The Lancet, vol. 382, no. 9903, pp. 1525–1533, 2013.

[2] F. Nakagawa, M. May, and A. Phillips, “Life expectancy living with HIV,” Current Opinion in Infectious Diseases, vol. 26, no. 1, pp. 17–25, 2013.

[3] L. F. Johnson, J. Mossong, R. E. Dorrington et al., “Life Expectancies of South African Adults Starting Antiretroviral Treatment: Collaborative Analysis of Cohort Studies,” PLoS Medicine, vol. 10, no. 4, article e1001418, 2013.

[4] M. T. May, M. Gompels, V. Delpech et al., “Impact on life expectancy of HIV-1 positive individuals of CD4+ cell count and viral load response to antiretroviral therapy,” AIDS, vol. 28, no. 8, pp. 1193–1202, 2014.

[5] E. J. Wing, "HIV and aging,” International Journal of Infectious Diseases, vol. 53, pp. 61–68, 2016.

[6] IeDEA Pediatric Working Group, "Taking a critical look at the UNAIDS global estimates on paediatric and adolescent HIV survival and death,” Journal of the International AIDS Society, vol. 20, no. 1, article 21952, 2017.

[7] L. Cockerham, R. Scherzer, A. Zolopa et al., “Association of HIV Infection, Demographic and Cardiovascular Risk Factors With All-Cause Mortality in the Recent HAART Era,” Journal of Acquired Immune Deficiency Syndromes, vol. 53, no. 1, pp. 102–106, 2010.

[8] The Antiretroviral Therapy Cohort Collaboration, “Mortality of HIV-infected patients starting potent antiretroviral therapy: comparison with the general population in nine industrialized countries,” International Journal of Epidemiology, vol. 38, no. 6, pp. 1624–1633, 2009.

[9] T. M. Rickabaugh, R. D. Kilpatrick, L. E. Hultin et al., “The Dual Impact of HIV-1 Infection and Aging on Naive CD4+ T-Cells: Additive and Distinct Patterns of Impairment,” PLoS One, vol. 6, no. 1, article e16459, 2011.

[10] R. B. Effros, C. V. Fletcher, K. Gebo et al., “Aging and Infectious Diseases: Workshop on HIV Infection and Aging: What Is Known and Future Research Directions,” Clinical Infectious Diseases, vol. 47, no. 4, pp. 542–553, 2008.

[11] B. K. Kennedy, S. L. Berger, A. Brunet et al., “Geroscience: Linking Aging to Chronic Disease,” Cell, vol. 159, no. 4, pp. 709–713, 2014.

[12] K. M. Erlandson, A. A. Allshouse, C. M. Jankowski et al., “Association of Functional Impairment with Inflammation and Immune Activation in HIV Type 1–Infected Adults Receiving Effective Antiretroviral Therapy,” The Journal of Infectious Diseases, vol. 208, no. 2, pp. 249–259, 2013.

[13] D. A. Piggott, A. D. Muzzaile, S. H. Mehta et al., “Frailty, HIV Infection, and Mortality in an Aging Cohort of Injection Drug Users,” PLoS One, vol. 8, no. 1, article e54910, 2013.

[14] K. Shah, T. N. Hilton, L. Myers, J. F. Pinto, A. E. Luque, and W. J. Hall, “A New Frailty Syndrome: Central Obesity and Frailty in Older Adults with the Human Immunodeficiency Virus,” Journal of the American Geriatrics Society, vol. 60, no. 3, pp. 545–549, 2012.

[15] L. Desquilbet, L. P. Jacobson, L. P. Fried et al., “HIV-1 Infection Is Associated With an Earlier Occurrence of a Phenotype Related to Frailty,” The Journals of Gerontology. Series A, Biological Sciences and Medical Sciences, vol. 62, no. 11, pp. 1279–1286, 2007.

[16] C. Lagathu, A. Cossarizza, V. Bérézat, M. Nasi, J. Capeau, and M. Pinti, “Basic science and pathogenesis of ageing with HIV,” AIDS, vol. 31, Supplement 2, pp. S105–S119, 2017.

[17] S. Desai and A. Landay, “Early Immune Senescence in HIV Disease,” Current HIV/AIDS Reports, vol. 7, no. 1, pp. 4–10, 2010.

[18] G. Hewitt, D. Jurk, F. D. M. Marques et al., “Telomeres are favoured targets of a persistent DNA damage response in ageing and stress-induced senescence,” Nature Communications, vol. 3, no. 1, p. 708, 2012.

[19] M. Fumagalli, F. Rossiello, M. Clerici et al., “Telomeric DNA damage is irreparable and causes persistent DNA-damage-response activation,” Nature Cell Biology, vol. 14, no. 4, pp. 355–365, 2012.

[20] A. M. Olovnikov, “Telomeres, telomerase, and aging: Origin of the theory,” Experimental Gerontology, vol. 31, no. 4, pp. 443–448, 1996.

[21] M. Armanios and E. H. Blackburn, “The telomere syndromes,” Nature Reviews Genetics, vol. 13, no. 10, pp. 693–704, 2012.

[22] M. Armanios, J. K. Alder, E. M. Parry, B. Karim, M. A. Strong, and C. W. Greider, “Short Telomeres are Sufficient to Cause the Degenerative Defects Associated with Aging,” American Journal of Human Genetics, vol. 85, no. 6, pp. 823–832, 2009.

[23] G. Ballon, L. Ometto, E. Righetti et al., “Human Immunodeficiency Virus Type 1 Modulates Telomerase Activity in Peripheral Blood Lymphocytes,” The Journal of Infectious Diseases, vol. 183, no. 3, pp. 417–424, 2001.

[24] P. Bostik, G. L. Dodd, S. S. Patel, H. Kadivar, and A. A. Ansari, “Effect of Productive In Vitro Human Immunodeficiency Virus or Simian Immunodeficiency Virus Infection on Telomerase Activity in Lymphoid and Nonlymphoid Cells,” The Journal of Infectious Diseases, vol. 185, no. 7, pp. 999–1001, 2002.

[25] O. Franzese, R. Adamo, M. Policotta et al., “Telomerase activity, hTERT expression, and phosphorylation are downregulated in CD4+ T lymphocytes infected with human immunodeficiency virus type 1 (HIV-1),” Journal of Medical Virology, vol. 79, no. 5, pp. 639–646, 2007.

[26] N. P. Weng, B. L. Levine, C. H. June, and R. J. Hodes, “Regulated expression of telomerase activity in human T lymphocyte development and activation,” The Journal of Experimental Medicine, vol. 183, no. 6, pp. 2471–2479, 1996.

[27] N. P. Weng, K. S. Hathcock, and R. J. Hodes, “Regulation of Telomere Length and Telomerase in T and B Cells,” Immunity, vol. 9, no. 2, pp. 151–157, 1998.

[28] “UNAIDS 2019 estimates, Global AIDS Monitoring,” 2019, http://aidsinfo.unaids.org.

[29] A. J. Prendergast, P. Klernerman, and P. J. Goulder, “The impact of differential antiviral immunity in children and adults,” Nature Reviews Immunology, vol. 12, no. 9, pp. 636–648, 2012.

[30] E. Ricci, S. Malacrida, M. Zanchetta, M. Montagna, C. Giaquinto, and A. de Rossi, “Role of β-Defensin-1 Polymorphisms in Mother-to-Child Transmission of HIV-1,”
Precursor T cells and the generation of CD8+ T cells by anti-HIV therapy.
AIDS,” *Journal of the National Cancer Institute*, vol. 99, no. 12, pp. 962–972, 2007.

[61] E. Chiappini, L. Galli, P. A. Tovo et al., “Cancer Rates After Year 2000 Significantly Decrease in Children With Perinatal HIV Infection: A Study by the Italian Register for HIV Infection in Children,” *Journal of Clinical Oncology*, vol. 25, no. 1, pp. 97–101, 2007.

[62] B. H. Pollock, H. B. Jenson, C. T. Leach et al., “Risk Factors for Pediatric Human Immunodeficiency Virus–Related Malignancy,” *JAMA*, vol. 289, no. 18, pp. 2393–2399, 2003.

[63] B. U. Mueller, “Cancers in Children Infected With the Human Immunodeficiency Virus,” *The Oncologist*, vol. 4, no. 4, pp. 309–317, 1999.

[64] M. O. Granovsky, B. U. Mueller, H. S. Nicholson, P. S. Rosenberg, and C. S. Rabkin, “Cancer in human immunodeficiency virus-infected children: a case series from the Children’s Cancer Group and the National Cancer Institute,” *Journal of Clinical Oncology*, vol. 16, no. 5, pp. 1729–1735, 1998.

[65] R. J. Biggar, M. Frisch, and J. J. Goedert, “Risk of Cancer in Children With AIDS,” *JAMA*, vol. 284, no. 2, pp. 205–209, 2000.

[66] M. R. Petrarra, R. Freguia, K. Giasemis, M. Zanchetta, and A. D. Rossi, “Epstein-Barr virus–driven lymphomagenesis in the context of human immunodeficiency virus type 1 infection,” *Frontiers in Microbiology*, vol. 4, p. 311, 2013.

[67] E. C. Breen, S. K. Hussain, L. Magnantay et al., “B-Cell Stimulatory Cytokines and Markers of Immune Activation Are Elevated Several Years Prior to the Diagnosis of Systemic AIDS-Associated Non-Hodgkin B-Cell Lymphoma,” *Cancer Epidemiology, Biomarkers & Prevention*, vol. 20, no. 7, pp. 1303–1314, 2011.

[68] R. F. Ambinder, K. Bhatia, O. Martinez-Maza, and R. Mitsuyasu, “Cancer biomarkers in HIV patients,” *Current Opinion in HIV and AIDS*, vol. 5, no. 6, pp. 531–537, 2010.

[69] E. P. Simard, M. S. Shiels, K. Bhatia, and E. A. Engels, “Long-term Cancer Risk among People Diagnosed with AIDS during Childhood,” *Cancer Epidemiology Biomarkers & Prevention*, vol. 21, no. 1, pp. 148–154, 2012.

[70] H. Kest, S. Brogly, G. McSherry, B. Dashefsky, J. Oleske, and G. R. Seage III, “Malignancy in Perinatally Human Immunodeficiency Virus-Infected Children in the United States,” *The Pediatric Infectious Disease Journal*, vol. 24, no. 3, pp. 237–242, 2005.

[71] M. R. Petrarra, M. Penazzato, W. Massavon et al., “Epstein-Barr Virus Load in Children Infected With Human Immunodeficiency Virus Type 1 in Uganda,” *The Journal of Infectious Diseases*, vol. 210, no. 3, pp. 392–399, 2014.

[72] D. L. Regidor, R. Detels, E. C. Breen et al., “Effect of highly active antiretroviral therapy on biomarkers of B-lymphocyte activation and inflammation,” *AIDS*, vol. 25, no. 3, pp. 303–314, 2011.

[73] D. C. Douek, M. Roederer, and R. A. Koup, “Emerging Concepts in the Immunopathogenesis of AIDS,” *Annual Review of Medicine*, vol. 60, no. 1, pp. 471–484, 2009.

[74] R. B. Effros, “Replicative senescence of CD8 T cells: potential effects on cancer immune surveillance and immunotherapy,” *Cancer Immunology, Immunotherapy*, vol. 53, no. 10, pp. 925–933, 2004.

[75] M. Fumagalli and F. d’Adda di Fagagna, “SASPense and DDRama in cancer and ageing,” *Nature Cell Biology*, vol. 11, no. 8, pp. 921–923, 2009.

[76] J. Campisi, J. K. Andersen, P. Kapahi, and S. Melov, “Cellular senescence: a link between cancer and age-related degenerative disease?”, *Seminars in Cancer Biology*, vol. 21, no. 6, pp. 354–359, 2011.

[77] A. S. Fauci and R. C. Desrosiers, *Retroviruses*, Cold Spring Harbor Laboratory Press, USA, 1997.

[78] G. Pantaleo and A. S. Fauci, “Immunopathogenesis of HIV infection,” *Annual Review of Microbiology*, vol. 50, no. 1, pp. 825–854, 1996.

[79] O. Franzese, M. L. Barbaccia, E. Bonmassar, and G. Graziani, “Beneficial and Detrimental Effects of Antiretroviral Therapy on HIV-Related Immunosuppression,” *Chemotherapy*, vol. 63, no. 2, pp. 64–75, 2018.

[80] J. N. Dock and R. B. Effros, “Role of CD8 T Cell Replicative Senescence in Human Aging and in HIV-mediated Immunosuppression,” *Aging and Disease*, vol. 2, no. 5, pp. 382–397, 2011.

[81] A. N. Akbar and J. M. Fletcher, “Memory T cell homeostasis and senescence during aging,” *Current Opinion in Immunology*, vol. 17, no. 5, pp. 480–485, 2005.

[82] J. J. Goronzy, J. W. Fulbright, C. S. Crowson, G. A. Poland, W. M. O’Fallon, and C. M. Weyand, “Value of Immunological Markers in Predicting Responsiveness to Influenza Vaccination in Elderly Individuals,” *Journal of Virology*, vol. 75, no. 24, pp. 12182–12187, 2001.

[83] M. Clerici, M. Saresella, F. Colombo et al., “T-lymphocyte maturation abnormalities in uninfected newborns and children with vertical exposure to HIV,” *Blood*, vol. 96, no. 12, pp. 3866–3871, 2000.

[84] T. W. McCloskey, N. Kohn, M. Lesser, S. Bakshi, and S. Pahwa, “Immunophenotypic analysis of HIV-infected children: Alterations within the first year of life, changes with disease progression, and longitudinal analyses of lymphocyte subsets,” *Cytometry*, vol. 46, no. 3, pp. 157–165, 2001.

[85] W. T. Shearer, K. A. Easley, J. Goldfarb et al., “Prospective 5-year study of peripheral blood CD4”, CD8”, and CD19”/CD20” lymphocytes and serum lgs in children born to HIV-1+ women,” *The Journal of Allergy and Clinical Immunology*, vol. 106, no. 3, pp. 559–566, 2000.

[86] M. Kharbanda, T. W. McCloskey, R. Pahwa, M. Sun, and S. Pahwa, “Alterations in T-Cell Receptor Vβ Repertoire of CD4 and CD8 T Lymphocytes in Human Immunodeficiency Virus-Infected Children,” *Clinical and Diagnostic Laboratory Immunology*, vol. 10, no. 1, pp. 53–58, 2003.

[87] T. Seers, P. Vassallo, K. Pollock, J. P. Thornhill, S. Fidler, and C. Foster, “CD4/CD8 ratio in children with perinatally acquired HIV-1 infection,” *HIV Medicine*, vol. 19, no. 9, pp. 668–672, 2018.

[88] C. Mussini, P. Lorenzini, A. Cozzi-Leprì et al., “CD4/CD8 ratio normalisation and non-AIDS-related events in individuals with HIV who achieve viral load suppression with antiretroviral therapy: an observational cohort study,” *The Lancet HIV*, vol. 2, no. 3, pp. e98–e106, 2015.

[89] M. Muench, A. J. Prendergast, and P. J. Goulder, “Immunity to HIV in early life,” *Frontiers in Immunology*, vol. 12, p. 391, 2014.

[90] T. Sainz, S. Serrano-Villar, L. Diaz et al., “The CD4/CD8 ratio as a marker T-cell activation, senescence and activation/exhaustion in treated HIV-infected children and young adults,” *AIDS*, vol. 27, no. 9, pp. 1513–1516, 2013.

[91] P. J. Linton and K. Dorshkind, “Age-related changes in lymphocyte development and function,” *Nature Immunology*, vol. 5, no. 2, pp. 133–139, 2004.
[92] R. L. Rabin, M. Roederer, Y. Maldonado, A. Petru, L. A. Herzenberg, and L. A. Herzenberg, “Altered representation of naive and memory CD8 T cell subsets in HIV-infected children,” *The Journal of Clinical Investigation*, vol. 95, no. 5, pp. 2054–2060, 1995.

[93] S. Resino, R. Correa, J. M. Bellón, and M. A. Muñoz-Fernández, “Preserved immune system in long-term asymptomatic vertically HIV-1 infected children,” *Clinical and Experimental Immunology*, vol. 132, no. 1, pp. 105–112, 2003.

[94] K. A. Jordan, S. N. Furlan, V. D. Gonzalez et al., “CD8 T cell effector maturation in HIV-1-infected children,” *Virology*, vol. 347, no. 1, pp. 117–126, 2006.

[95] J. D. Ahlers and I. M. Belyakov, “Memories that last forever: strategies for optimizing vaccine T-cell memory,” *Blood*, vol. 115, no. 9, pp. 1678–1689, 2010.

[96] J. Foldi, L. Kozhaya, B. McCarty et al., “HIV-Infected Children Have Elevated Levels of PD-1+ Memory CD4 T Cells With Low Proliferative Capacity and High Inflammatory Cytokine Effector Functions,” *The Journal of Infectious Diseases*, vol. 216, no. 6, pp. 641–650, 2017.

[97] M. Sperk, R. Domseлаar, and U. Neogi, “Immune Checkpoints as the Immune System Regulators and Potential Biomarkers in HIV-1 Infection,” *International Journal of Molecular Sciences*, vol. 19, no. 7, p. 2000, 2018.

[98] C. Fenwick, V. Joo, P. Jacquier et al., “T-cell exhaustion in HIV infection,” *Immunological Reviews*, vol. 292, no. 1, pp. 149–163, 2019.

[99] Y. Belkaid, “Regulatory T cells and infection: a dangerous necessity,” *Nature Reviews Immunology*, vol. 7, no. 11, pp. 875–888, 2007.

[100] D. Holmes, Q. Jiang, L. Zhang, and L. Su, “Foxp3 and Treg cells in HIV-1 infection and immuno-pathogenesis,” *Immunologic Research*, vol. 41, no. 3, pp. 248–266, 2008.

[101] D. A. A. Vignali, L. W. Collison, and C. J. Workman, “How regulatory T cells work,” *Nature Reviews Immunology*, vol. 8, no. 7, pp. 523–532, 2008.

[102] E. M. Aandahl, J. Michaelissson, W. J. Moretto, F. M. Hecht, and D. F. Nixon, “Human CD4 CD25 Regulatory T Cells Control T-Cell Responses to Human Immunodeficiency Virus and Cytomegalovirus Antigens,” *Journal of Virology*, vol. 78, no. 5, pp. 2454–2459, 2004.

[103] L. Weiss, V. Donkova-Petri, L. Caccavelli, M. Balbo, C. Carbonneil, and Y. Levy, “Human immunodeficiency virus–driven expansion of CD4CD25 regulatory T cells, which suppress HIV-specific CD4 T-cell responses in HIV-infected patients,” *Blood*, vol. 104, no. 10, pp. 3249–3256, 2004.

[104] L. Weiss, C. Piketty, L. Assoumou et al., “Relationship between Regulatory T Cells and Immune Activation in Human Immunodeficiency Virus-Infected Patients Interrupting Antiretroviral Therapy,” *PloS One*, vol. 5, no. 7, article e11659, 2010.

[105] M. P. Eggema, B. Barughare, N. Jones et al., “Depletion of Regulatory T Cells in HIV Infection Is Associated with Immune Activation,” *Journal of Immunology*, vol. 174, no. 7, pp. 4407–4414, 2005.

[106] A. Kinter, J. McNally, L. Riggan, R. Jackson, G. Roby, and A. S. Fauci, “Suppression of HIV-specific T cell activity by lymph node CD25 regulatory T cells from HIV-infected individuals,” *Proceedings of the National Academy of Sciences of the United States of America*, vol. 104, no. 9, pp. 3390–3395, 2007.

[107] L. Kolte, J. C. Gaardbo, K. Skogstrand, L. P. Ryder, A. K. Erbsbøll, and S. D. Nielsen, “Increased levels of regulatory T cells (Tregs) in human immunodeficiency virus-infected patients after 5 years of highly active anti-retroviral therapy may be due to increased thymic production of naive Tregs,” *Clinical and Experimental Immunology*, vol. 155, no. 1, pp. 44–52, 2009.

[108] J. C. Gaardbo, S. D. Nielsen, S. J. Vedel et al., “Regulatory T cells in human immunodeficiency virus-infected patients are elevated and independent of immunological and virological status, as well as initiation of highly active anti-retroviral therapy,” *Clinical and Experimental Immunology*, vol. 154, no. 1, pp. 80–86, 2008.

[109] R. Fregua, K. Giansen, I. Mosconi et al., “Regulatory T cells and chronic immune activation in human immunodeficiency virus 1 (HIV-1)-infected children,” *Clinical and Experimental Immunology*, vol. 164, no. 3, pp. 373–380, 2011.

[110] S. Pallikkuth, L. de Armas, S. Rinaldi, and S. Pahta, “T Follicular Helper Cells and B Cell Dysfunction in Aging and HIV-1 Infection,” *Frontiers in Immunology*, vol. 8, article 1380, 2017.

[111] L. R. de Armas, N. Cotugno, S. Pallikkuth et al., “Induction of IL21in Peripheral T Follicular Helper Cells Is an Indicator of Influenza Vaccine Response in a Previously Vaccinated HIV-Infected Pediatric Cohort,” *Journal of Immunology*, vol. 198, no. 5, pp. 1995–2005, 2017.

[112] F. Sallusto, J. Geginat, and A. Lanzavecchia, “Central Memory and Effector Memory T Cell Subsets: Function, Generation, and Maintenance,” *Annual Review of Immunology*, vol. 22, pp. 745–763, 2004.

[113] J. M. Brenchley, N. J. Karandikar, M. R. Betts et al., “Expression of CD57 defines replicative senescence and antigen-induced apoptotic death of CD8+ T cells,” *Blood*, vol. 101, no. 7, pp. 2711–2720, 2003.

[114] A. Cagigi, S. Rinaldi, A. di Martino et al., “Premature immune senescence during HIV-1 vertical infection relates with response to influenza vaccination,” *The Journal of Allergy and Clinical Immunology*, vol. 133, no. 2, pp. 592–594.e1, 2014.

[115] M. Hart, A. Steel, S. A. Clark et al., “Loss of Discrete Memory B Cell Subsets Is Associated with Impaired Immunization Responses in HIV-1 Infection and May Be a Risk Factor for Invasive Pneumococcal Disease,” *Journal of Immunology*, vol. 178, no. 12, pp. 8212–8220, 2007.

[116] G. K. Siberry, K. Patel, W. J. Bellini et al., “Immunity to Measles, Mumps, and Rubella in US Children With Perinatal HIV Infection or Perinatal HIV Exposure Without Infection,” *Clinical Infectious Diseases*, vol. 61, no. 6, pp. 988–995, 2015.

[117] S. Moir, J. Ho, A. Malaspinia et al., “Evidence for HIV-associated B cell exhaustion in a dysfunctional memory B cell compartment in HIV-infected viremic individuals,” *The Journal of Experimental Medicine*, vol. 205, no. 8, pp. 1797–1805, 2008.

[118] S. Rinaldi, S. Pallikkuth, V. K. George et al., “Paradoxical aging in HIV: immune senescence of B Cells is most prominent in young age,” *Aging*, vol. 9, no. 4, pp. 1307–1325, 2017.

[119] P. Palma, S. Rinaldi, N. Cotugno et al., “Premature B-cell senescence as a consequence of chronic immune activation: Implications for vaccination of immune compromised individuals,” *Human Vaccines & Immunotherapeutics*, vol. 10, no. 7, pp. 2083–2088, 2014.

[120] S. Moir and A. S. Fauci, “B cells in HIV infection and disease,” *Nature Reviews Immunology*, vol. 9, no. 4, pp. 235–245, 2009.
B-cell responses to HIV infection,” *Immunological Reviews*, vol. 275, no. 1, pp. 33–48, 2017.

R. Singh, A. Mukherjee, M. Singla et al., “Impact of HIV infection and highly active antiretroviral therapy (HAART) on B cell subpopulations in children,” *Journal of Medical Virology*, vol. 90, no. 7, pp. 1222–1231, 2018.

A. Cagli, S. Kinaldi, V. Santillii et al., “Premature aging of the immune system relates with increased anti-lymphocyte antibodies (ALA) after an immunization in HIV-1 infected and kidney transplanted patients,” *Clinical and Experimental Immunology*, vol. 174, no. 2, pp. 274–280, 2013.

Y. Bekele, M. Lemma, K. Bobosha et al., “Homing defects of B cells in HIV-1 infected children impair vaccination responses,” *Vaccine*, vol. 37, no. 17, pp. 2348–2355, 2019.

N. Cotugno, L. de Armas, S. Pallikkuth et al., “Perturbation of B Cell Gene Expression Persists in HIV-Infected Children Despite Effective Antiretroviral Therapy and Predicts H1N1 Response,” *Frontiers in Immunology*, vol. 8, article 1083, 2017.

L. R. de Armas, S. Pallikkuth, L. Pan et al., “Single Cell Profiling Reveals PTEN Overexpression in Influenza-Specific B cells in Aging HIV-infected individuals on Anti-retroviral Therapy,” *Scientific Reports*, vol. 9, no. 1, article 2482, 2019.

J. V. Giorgi, R. H. Lyles, J. L. Matud et al., “Predictive Value of Immunologic and Virologic Markers After Long or Short Duration of HIV-1 Infection,” *Journal of Acquired Immune Deficiency Syndromes*, vol. 29, no. 4, pp. 346–355, 2002.

J. M. Brenchley, D. A. Price, T. W. Schacker et al., “Microbial translocation is a cause of systemic immune activation in chronic HIV infection,” *Nature Medicine*, vol. 12, no. 12, pp. 1365–1371, 2006.

Q. Zhang, M. Raouf, Y. Chen et al., “Circulating mitochondrial DAMPs cause inflammatory responses to injury,” *Nature*, vol. 464, no. 7285, pp. 104–107, 2010.

K. Van Crombruggen, F. Jacob, N. Zhang, and C. Bachert, “Damage-associated molecular patterns and their receptors in upper airway pathologies,” *Cellular and Molecular Life Sciences*, vol. 70, no. 22, pp. 4307–4321, 2013.

C. A. Janeway Jr. and R. Medzhitov, “Innate immune recognition,” *Annual Review of Immunology*, vol. 20, no. 1, pp. 197–216, 2002.

T. Sainz, M. Alvarez-Fuente, M. L. Navarro et al., “Subclinical Atherosclerosis and Markers of Immune Activation in HIV-Infected Children and Adolescents,” *JAIDS Journal of Acquired Immune Deficiency Syndromes*, vol. 65, no. 1, pp. 42–49, 2014.

D. Persaud, K. Patel, B. Karalius et al., “Influence of Age at Virologic Control on Peripheral Blood Human Immunodeficiency Virus Reservoir Size and Serostatus in Perinatally Infected Adolescents,” *JAMA Pediatrics*, vol. 168, no. 12, pp. 1138–1146, 2014.

S. Dirjalal-Fargo, V. El-Kamari, L. Weiner et al., “Altered intestinal permeability and fungal translocation in Ugandan children with human immunodeficiency virus,” *Clinical Infectious Diseases*, no. article ci6561, 2019.

J. C. Mudd and J. M. Brenchley, “Gut Mucosal Barrier Dysfunction, Microbial Dysbiosis, and Their Role in HIV-1 Disease Progression,” *The Journal of Infectious Diseases*, vol. 214, Supplement 2, pp. S58–S66, 2016.

P. Alvarez, M. Mwamzuka, F. Marshed et al., “Immune activation despite preserved CD4 T cells in perinatally HIV-infected children and adolescents,” *PLoS One*, vol. 12, no. 12, article e0190332, 2017.

M. Generoso, P. Alvarez, A. Kravietz et al., “High soluble CD163 levels correlate with disease progression and inflammation in Kenyan children with perinatal HIV-infection,” *AIDS*, vol. 34, no. 1, pp. 33–38, 2020.

F. C. Fitzgerald, E. Lhomme, K. Harris et al., “Microbial Translocation Does Not Drive Immune Activation in Ugandan Children Infected With HIV,” *The Journal of Infectious Diseases*, vol. 219, no. 1, pp. 89–100, 2019.

G. Breton, N. Chomont, H. Takata et al., “Programmed Death-1 Is a Marker for Abnormal Distribution of Naïve/Memory T Cell Subsets in HIV-1 Infection,” *Journal of Immunology*, vol. 191, no. 5, pp. 2194–2204, 2013.

C. L. Day, D. E. Kaufmann, P. Kiepiela et al., “PD-1 expression on HIV-specific T cells is associated with T-cell exhaustion and disease progression,” *Nature*, vol. 443, no. 7109, pp. 350–354, 2006.

L. Trautmann, L. Janbazian, N. Chomont et al., “Upregulation of PD-1 expression on HIV-specific CD8+ T cells leads to reversible immune dysfunction,” *Nature Medicine*, vol. 12, no. 10, pp. 1198–1202, 2006.

A. Prendergast, M. O’Callaghan, E. Menson et al., “Factors Influencing T Cell Activation and Programmed Death 1 Expression in HIV-Infected Children,” *AIDS Research and Human Retroviruses*, vol. 28, no. 5, pp. 465–468, 2012.

I. Siewanyancya, C. A. Baker, T. Ruel et al., “The Distribution and Immune Profile of T Cell Subsets in HIV-Infected Children from Uganda,” *AIDS Research and Human Retroviruses*, vol. 25, no. 1, pp. 65–71, 2009.

R. Banga, F. A. Procopio, A. Noto et al., “PD-1+ and follicular helper T cells are responsible for persistent HIV-1 transcription in treated aviremic individuals,” *Nature Medicine*, vol. 22, no. 7, pp. 754–761, 2016.

D. M. Muema, G. N. Macharia, A. S. Hassan et al., “Control of Viremia Enables Acquisition of Resting Memory B Cells with Age and Normalization of Activated B Cell Phenotypes in HIV-Infected Children,” *Journal of Immunology*, vol. 195, no. 3, pp. 1082–1091, 2015.

M. R. Petrara, A. M. Cattelan, L. Sasset et al., “Impact of monotherapy on HIV-1 reservoir, immune activation, and co-infection with Epstein-Barr virus,” *PLoS One*, vol. 12, no. 9, article e0185128, 2017.

H. Aggarwal, L. Khan, O. Chaudhary et al., “Alterations in B Cell Compartment Correlate with Poor Neutralization Response and Disease Progression in HIV-1 Infected Children,” *Frontiers in Immunology*, vol. 8, article 1697, 2017.

S. Giunco, A. Celeghin, K. Giansini, R. Dolcetti, S. Indraccolo, and A. de Rossi, “Cross talk between EBV and telomerase: the role of TERT and NOTCH2 in the switch of latent/lytic cycle of the virus,” *Cell Death & Disease*, vol. 6, no. 5, article e1774, 2015.

T. Tchkoninia, Y. Zhu, J. van Deursen, J. Campisi, and J. L. Kirkland, “Cellular senescence and the senescent secretory phenotype: therapeutic opportunities,” *Journal of Clinical Investigation*, vol. 123, no. 3, pp. 966–972, 2013.

J. W. Shay, “Telomeres and aging,” *Current Opinion in Cell Biology*, vol. 52, pp. 1–7, 2018.

S. E. Artandi and R. DePinho, “Telomeres and telomerase in cancer,” *Carcinogenesis*, vol. 31, no. 1, pp. 9–18, 2010.
[152] T. De Meyer, E. R. Rietzschel, M. L. De Buyzere, W. Van Criekinge, and S. Bekaert, “Telomere length and cardiovascular aging: The means to the ends?,” *Ageing Research Reviews*, vol. 10, no. 2, pp. 297–303, 2011.

[153] R. M. Cawthon, K. R. Smith, E. O’Brien, A. Sivatchenko, and R. A. Kerber, “Association between telomere length in blood and mortality in people aged 60 years or older,” *The Lancet*, vol. 361, no. 9355, pp. 393–395, 2003.

[154] P. Willeit, J. Willeit, A. Brandstätter et al., “Cellular Aging Reflected by Leukocyte Telomere Length Predicts Advanced Atherosclerosis and Cardiovascular Disease Risk,” *Arteriosclerosis, Thrombosis, and Vascular Biology*, vol. 30, no. 8, pp. 1649–1656, 2010.

[155] P. C. Haycock, E. E. Heydon, S. Kaptoge, A. S. Butterworth, A. Thompson, and P. Willeit, “Leucocyte telomere length and risk of cardiovascular disease: systematic review and meta-analysis,” *BMJ*, vol. 349, 2014.

[156] A. L. Fitzpatrick, R. A. Kronmal, J. P. Gardner et al., “Leukocyte telomere length and cardiovascular disease in the cardiovascular health study,” *American Journal of Epidemiology*, vol. 165, no. 1, pp. 14–21, 2007.

[157] K. D. Salpea and S. E. Humphries, “Telomere length in atherosclerosis and diabetes,” *Atherosclerosis*, vol. 209, no. 1, pp. 35–38, 2010.

[158] A. L. Fitzpatrick, R. A. Kronmal, M. Kimura et al., “Leukocyte Telomere Length and Mortality in the Cardiovascular Health Study,” *The Journal of Gerontology Series A: Biological Sciences and Medical Sciences*, vol. 66A, no. 4, pp. 421–429, 2011.

[159] E. S. Epel, S. S. Merkin, R. Cawthon et al., “The rate of leukocyte telomere shortening predicts mortality from cardiovascular disease in elderly men: a novel demonstration,” *Aging*, vol. 1, no. 1, pp. 81–88, 2008.

[160] K. J. Turner, V. Vasu, and D. Griffin, “Telomere Biology and Human Phenotype,” *Cell*, vol. 8, no. 1, p. 73, 2019.

[161] P. Willeit, J. Raschenberger, E. E. Heydon et al., “Leucocyte Telomere Length and Risk of Type 2 Diabetes Mellitus: New Prospective Cohort Study and Literature-Based Meta-Analysis,” *PLoS One*, vol. 9, no. 11, article e112483, 2014.

[162] N. C. Y. You, B. H. Chen, Y. Song et al., “A Prospective Study of Leukocyte Telomere Length and Risk of Type 2 Diabetes in Postmenopausal Women,” *Diabetes*, vol. 61, no. 11, pp. 2998–3002, 2012.

[163] P. Thomas, N. J. O’Callaghan, and M. Fenech, “Telomere length in white blood cells, buccal cells and brain tissue and its variation with ageing and Alzheimer’s disease,” *Mechanisms of Ageing and Development*, vol. 129, no. 4, pp. 183–190, 2008.

[164] L. Panossian, V. R. Porter, H. F. Valenzuela et al., “Telomere shortening in T cells correlates with Alzheimer’s disease status,” *Neurobiology of Aging*, vol. 24, no. 1, pp. 77–84, 2003.

[165] L. S. Honig, N. Schupf, J. H. Lee, M. X. Tang, and R. Mayeux, “Shorter telomeres are associated with mortality in those with APOE ε4 and dementia,” *Annals of Neurology*, vol. 60, no. 2, pp. 181–187, 2006.

[166] F. Grodstein, M. van Oijen, M. C. Irizarry et al., “Shorter Telomeres May Mark Early Risk of Dementia: Preliminary Analysis of 62 Participants from the Nurses’ Health Study,” *PLoS One*, vol. 3, no. 2, article e1590, 2008.

[167] T. Hochstrasser, J. Marksteiner, and C. Humpel, “Telomere length is age-dependent and reduced in monocytes of alzheimer patients,” *Experimental Gerontology*, vol. 47, pp. 160–163, 2012.

[168] G. Watfa, C. Dragonas, T. Brosche et al., “Study of telomere length and different markers of oxidative stress in patients with Parkinson’s disease,” *The Journal of Nutrition, Health & Aging*, vol. 15, no. 4, pp. 277–281, 2011.

[169] J. Z. Guan, T. Maeda, M. Sugano et al., “A Percentage Analysis of the Telomere Length in Parkinson’s Disease Patients,” *The Journals of Gerontology Series A: Biological Sciences and Medical Sciences*, vol. 63, no. 5, pp. 467–473, 2008.

[170] M. A. Blasco, “Telomeres and human disease: ageing, cancer and beyond,” *Nature Reviews Genetics*, vol. 6, no. 8, pp. 611–622, 2005.

[171] S. Giunco, E. Rampazzo, A. Celeghin, M. R. Petrara, and A. de Rossi, “Telomere and Telomerase in Carcinogenesis: Their Role as Prognostic Biomarkers,” *Current Pathobiology Reports*, vol. 3, no. 4, pp. 315–328, 2015.

[172] A. Esciribano, S. Pastor, A. Reula et al., “Accelerated telomere attrition in children and teenagers with α1-antitrypsin deficiency,” *The European Respiratory Journal*, vol. 48, no. 2, pp. 350–358, 2016.

[173] S. Bhala, A. F. Best, N. Giri et al., “CNS manifestations in patients with telomere biology disorders,” *Neurology Genetics*, vol. 5, no. 6, p. 370, 2019.

[174] S. H. Donze, V. Cod, L. Damen et al., “Evidence for Accelerated Biological Aging in Young Adults with Prader–Willi Syndrome,” *The Journal of Clinical Endocrinology & Metabolism*, vol. 105, no. 6, 2020.

[175] S. Ackermann and M. Fischer, “Telomere Maintenance in Pediatric Cancer,” *International Journal of Molecular Sciences*, vol. 20, no. 23, p. 5836, 2019.

[176] L. Song, B. Liu, M. Wu et al., “Prenatal Exposure to Phthalates and Newborn Telomere Length: A Birth Cohort Study in Wuhan, China,” *Environmental Health Perspectives*, vol. 127, no. 8, article 087007, 2019.

[177] D. B. P. Clemente, L. Maitre, M. Bustamante et al., “Obesity is associated with shorter telomeres in 8-year-old children,” *Scientific Reports*, vol. 9, no. 1, 2019.

[178] A. Lamprokostopoulou, G. Moschonis, Y. Manios et al., “Childhood obesity and leucocyte telomere length,” *European Journal of Clinical Investigation*, vol. 49, no. 12, article e13178, 2019.

[179] J. K. Alder, V. S. Hanumanthu, M. A. Strong et al., “Diagnostic utility of telomere length testing in a hospital-based setting,” *Proceedings of the National Academy of Sciences of the United States of America*, vol. 155, no. 10, pp. 2358–2365, 2018.

[180] J. C. Y. Liu, J. M. Leung, D. A. Ngan et al., “Absolute Leukocyte Telomere Length in HIV-Infected and Uninfected Individuals: Evidence of Accelerated Cell Senescence in HIV-Associated Chronic Obstructive Pulmonary Disease,” *PLoS One*, vol. 10, no. 4, article e0124426, 2015.

[181] S. Shin, V. K. Fitz, E. Petrow et al., “Soluble CD163 Is Associated With Shortened Telomere Length in HIV-Infected Patients,” *JAIDS Journal of Acquired Immune Deficiency Syndromes*, vol. 67, no. 4, pp. 414–418, 2014.

[182] D. A. L. Zanet, A. Thorne, J. Singer et al., “Association Between Short Leukocyte Telomere Length and HIV Infection in a Cohort Study: No Evidence of a Relationship With Antiretroviral Therapy,” *Clinical Infectious Diseases*, vol. 58, no. 9, pp. 1322–1332, 2014.
[183] S. Pathai, S. D. Lawn, C. E. Gilbert et al., “Accelerated biological ageing in HIV-infected individuals in South Africa,” AIDS, vol. 27, no. 15, pp. 2375–2384, 2013.

[184] A. Gonzalez-Serna, A. Ajaykumar, I. Gadawski et al., “Rapid Decrease in Peripheral Blood Mononucleated Cell Telomere Length After HIV Seroconversion, but Not HCV Seroconversion,” Journal of Acquired Immune Deficiency Syndromes, vol. 76, no. 1, pp. e29–e32, 2017.

[185] Y. Peng, I. S. Mian, and N. F. Lue, “Analysis of Telomerase Processivity,” Molecular Cell, vol. 7, no. 6, pp. 1201–1211, 2001.

[186] A. J. Gillis, A. P. Schuller, and E. Skordalakes, “Structure of the Tribolium castaneum telomerase catalytic subunit TERT,” Nature, vol. 455, no. 7213, pp. 633–637, 2008.

[187] E. Leeansyah, P. U. Cameron, A. Solomon et al., “Inhibition of Telomerase Activity by Human Immunodeficiency Virus (HIV) Nucleos(t)ide Reverse Transcriptase Inhibitors: A Potential Factor Contributing to HIV-Associated Accelerated Aging,” The Journal of Infectious Diseases, vol. 207, no. 7, pp. 1157–1165, 2013.

[188] D. E. Gomez, R. G. Armando, and D. F. Alonso, “AZT as a telomerase inhibitor,” Frontiers in Oncology, vol. 2, p. 113, 2012.

[189] N. Stella-Ascariz, R. Montejano, J. Rodriguez-Centeno et al., “Blood Telomere Length Changes After Ritonavir-Boosted Darunavir Combined With Raltegravir or Tenofovir-Emtricitabine in Antiretroviral-Naïve Adults Infected With HIV-1,” The Journal of Infectious Diseases, vol. 218, no. 10, pp. 1523–1530, 2018.

[190] R. Montejano, N. Stella-Ascariz, S. Monge et al., “Impact of Nucleos(t)ide Reverse Transcriptase Inhibitors on Blood Telomere Length Changes in a Prospective Cohort of Aviremic HIV–Infected Adults,” The Journal of Infectious Diseases, vol. 218, no. 10, pp. 1531–1540, 2018.

[191] A. Ajaykumar, H. Soudeyns, F. Kakkar et al., “Leukocyte Telomere Length at Birth and During the Early Life of Children Exposed to but Uninfected With HIV After In Utero Exposure to Antiretrovirals,” The Journal of Infectious Diseases, vol. 217, no. 5, pp. 710–720, 2018.

[192] Y. Wang, S. S. Brummel, E. Beilstein-Wedel et al., “Association between zidovudine-containing antiretroviral therapy exposure in utero and leukocyte telomere length at birth,” AIDS, vol. 33, no. 13, pp. 2091–2096, 2019.

[193] S. Shiau, R. Strehlau, J. Shen et al., “Biomarkers of Aging in HIV-Infected Children on Suppressive Antiretroviral Therapy,” Journal of Acquired Immune Deficiency Syndromes, vol. 78, no. 5, pp. 549–556, 2018.

[194] S. Paghera, E. Quiros-Roldan, A. Sottini, M. Properzi, F. Castelli, and L. Imberti, “Lymphocyte homeostasis is maintained in perinatally HIV-infected patients after three decades of life,” Immunity & Ageing, vol. 16, no. 1, p. 26, 2019.